Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets ExpertiseGlobeNewsWire · Oct 14, 2026
Tempest signs related-party R&D pact, reshapes leadershipDefense World · Sep 29, 2026
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of DirectorsGlobeNewsWire · Sep 23, 2026
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving PremarketBenzinga · Sep 16, 2026
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T PlatformGlobeNewsWire · Sep 15, 2026
Tempest Therapeutics Announces Up to $7.5 Million Private PlacementGlobeNewsWire · Sep 11, 2026Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.30 | -$0.34 | Miss |
| May 14, 2026 | -$0.28 | -$2.53 | Miss |
| Mar 31, 2026 | -$0.62 | -$0.62 | Beat |
| Nov 5, 2025 | -$3.27 | -$0.79 | Beat |
| Aug 11, 2025 | -$3.23 | -$2.07 | Beat |
| May 13, 2025 | -$3.71 | -$3.16 | Beat |